Ardelyx (ARDX) Change in Receivables (2013 - 2026)
Ardelyx (ARDX) reported Change in Receivables of $11.0 million for Q1 2026, up 197.81% on a YoY basis from $3.7 million in Q1 2025, and up 330.83% quarter-over-quarter from -$4.8 million in Q4 2025.
Ardelyx (ARDX) Change in Receivables (2013 - 2026) Analysis & Trends
Ardelyx has reported Change in Receivables for 11 years, with the latest figure at $11.0 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Receivables rose 197.81% year-over-year to $11.0 million; the trailing twelve-month figure through Mar 2026 stood at $36.4 million (up 98.71% YoY), and the FY2025 full-year result was $14.1 million, down 60.35% from the prior year.
- Change in Receivables for Q1 2026 stood at $11.0 million, up from -$4.8 million in the prior quarter.
- The five-year high for Change in Receivables was $34.2 million in Q3 2023, with the low at -$21.2 million in Q4 2023.
- Historically, Change in Receivables has averaged $4.8 million across 5 years, with a median of $4.4 million in 2023.
- The largest YoY upside for Change in Receivables was 8329.88% in 2023 against a maximum downside of 940.87% in 2023.
- Ardelyx's Change in Receivables stood at $2.5 million in 2022, then slumped by 940.87% to -$21.2 million in 2023, then jumped by 121.24% to $4.5 million in 2024, then slumped by 205.59% to -$4.8 million in 2025, then soared by 330.83% to $11.0 million in 2026.
- The last three Change in Receivables figures came in at $11.0 million (Q1 2026), -$4.8 million (Q4 2025), and $14.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Ardelyx | 1.49 Bn | 1.25 Bn | 89.66 Mn | 10.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.99 Mn |
| Mar 31, 2026 | 10.99 Mn |
| Dec 31, 2025 | -4.76 Mn |
| Dec 31, 2025 | -4.76 Mn |
| Sep 30, 2025 | 14.06 Mn |
| Sep 30, 2025 | 14.06 Mn |
| Jun 30, 2025 | 16.09 Mn |
| Jun 30, 2025 | 16.09 Mn |
| Mar 31, 2025 | -11.24 Mn |
| Mar 31, 2025 | -11.24 Mn |
| Dec 31, 2024 | 4.51 Mn |
| Dec 31, 2024 | 4.51 Mn |
| Sep 30, 2024 | 15.95 Mn |
| Sep 30, 2024 | 15.95 Mn |
| Jun 30, 2024 | 9.08 Mn |
| Jun 30, 2024 | 9.08 Mn |
| Mar 31, 2024 | 6.13 Mn |
| Mar 31, 2024 | 6.13 Mn |
| Dec 31, 2023 | -21.23 Mn |
| Dec 31, 2023 | -21.23 Mn |